VEGFA and neoplasm: A potential explanation for this therapy success could be that the combination of oncolytic vaccinia virus and anti-VEGF antibody allows a better delivery and/or better interaction between the antibody and VEGF in the tumor tissue when compared to systemic delivered antibody alone.